Alaxo Airway Stents Engages CPR Strategic Marketing & Communications for North America/Global Expansion
Nasal Breathing Solutions for Snoring, Sleep Apnea, Athletic Performance
PHOENIX, December 22, 2020 (Newswire.com) - Alaxo Airway Stents (Alaxo), providers of FDA and Health Canada registered, internationally patented, innovative stent-based therapies to support healthy, natural, nasal breathing solutions for snoring, sleep apnea and enhanced athletic performance, has selected CPR Strategic Marketing Communicationsto accelerate corporate growth, provider prescribing and patient adoption of Alaxo's four stent products which can potentially replace existing snoring devices, as well as CPAP machines used to treat snoring and sleep apnea. Alaxo stents have been identified as a potential treatment for coronavirus-based viruses due to increased production of inhaled nitric oxide as an evidence-based, effective therapeutic for imminent and manifested respiratory insufficiency conditions.
Terry Bayliss, CEO, Alaxo, says, "The CPR team has the expertise and track record for designing and implementing compelling, credible marketing communications campaigns for leading healthcare companies worldwide, and we will rely upon its guidance to gain significant market traction for Alaxo."
Alaxo stents support other quality of life issues, including allergies, rhinitis, chronic rhinitis, sinusitis and allergic rhinitis. In addition to nighttime use, the Alaxo stent can be worn throughout the day, enhancing individual general health and well-being.
Joseph Carabello, president and CEO, CPR, says, "We're very excited to play a role in helping the Alaxo team build on its achievements, expand its market and gain even greater levels of credibility, recognition and success. Our shared goal is to help as many people as possible realize the benefits from Alaxo products - and help the world breathe better."
CPR develops and implements integrated business-to-business and direct-to-consumer positioning campaigns that drive market awareness and increased revenues for healthcare companies.
With 30+ years of experience serving life sciences companies, medical practices, hospitals, privately held entities, and not-for-profit organizations, CPR maintains a footprint in the areas of Life Sciences and medical devices, healthcare providers, employers/payers, managed care organizations, digital health, telehealth and healthcare information management and technology.
CPR delivers strategic market intelligence, rich content, interactive capabilities and rewarding affiliations that help differentiate brands and services in a competitive environment.
Over three decades, CPR has developed strong relationships in the healthcare delivery community spanning hospitals/health systems, medical practices and provider-sponsored organizations, commercial and government payers, and consumers. These include senior level contacts at regional and national organizations where CPR clients have enjoyed ongoing success.
CPR pioneered the development of telemedicine in the United States as a founding member of the Teladoc team. This early entree into the then nascent healthcare market segment gave CPR a head start in establishing itself as the leading public relations and marketing firm in telemedicine.
Alaxo offers FDA and Health Canada registered, internationally patented, innovative stent-based therapies to support healthy, natural, nasal breathing solutions for snoring, sleep apnea and enhanced athletic performance. Made of nitinol, a nickel-titanium alloy that has super-elastic characteristics, our innovative stents support the upper airway passage to allow for better airflow and easier breathing.
Source: Alaxo Airway Stents
Categories: Healthcare Technology